- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
vimpat
Synonyms :
Class :
Anti-convulsant
Dosage Forms & Strengths
Tablet-Schedule V:
50mg,100mg,150mg,200mg
Injectable solution-Schedule V:
200mg/20ml
Oral solution-Schedule V:
10mg/ml
Dosage forms and strength:
Tablet-Schedule V:
50mg,100mg,150mg,200mg
Injectable solution-Schedule V:
200mg/20ml
Oral solution-Schedule V:
10mg/ml
Refer adult dosing
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
it may increase the effects of each other
may increase the risk of sedation
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may enhance the adverse/toxic effect of lacosamide
may enhance the adverse/toxic effect of lacosamide
may enhance the adverse/toxic effect of lacosamide
may enhance the adverse/toxic effect of lacosamide
may enhance the adverse/toxic effect of lacosamide
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
may increase the level by affecting hepatic enzyme CYP2C9 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
when both drugs are combined, there may be a decreased level of serum concentration of lacosamide
the effect of lacosamide is increased by fluorouracil by the action on CYP2C9/10 hepatic enzyme metabolism
fedratinib increases the effect of lacosamide by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
May diminish the effects of pharmacodynamic antagonism
may decrease the levels by unspecified interaction mechanism
May diminish the effects of pharmacodynamic antagonism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
May diminish the effects of pharmacodynamic antagonism
Frequency defined:
>10%
Tablets and oral solution
Dizziness (16-53%)
Diplopia (6-16%)
Blurred vision (2-16%)
Nausea (7-17%)
Vomiting (6-16%)
Fatigue (7-15%)
Ataxia (11-14%)
Nystagmus (2-10%)
IV
Fatigue (20-63%)
Somnolence (26-34%)
Headache (4-16%)
Diplopia (4-20%)
Nausea (14-24%)
Dry mouth (6-12%)
Vomiting (4-12%)
Fatigue (12-18%)
Chest pain (3-12%)
1-10%
Tablets and oral solution
Nystagmus (2-10%)
Memory impairment (1-6%)
Balance disorder (1-6%)
Diarrhea (3-5%)
Gait disturbance (<1-4%)
Asthenia (1-3%)
Vertigo (1-4%)
Pruritus (2-3%)
Depression (2%)
IV
Oral paresthesia (4-8%)
Oral hypoesthesia (5-8%)
Diarrhea (4-8%)
Paresthesia (4-8%)
Gait disturbance (2-8%)
Hyperhidrosis (2-8%)
Tremor (4-6%)
Abnormal coordination (3-6%)
Pruritus (4-6%)
Pregnancy consideration: The drug may cross the placenta and can be detected in the serum of the newborn.
Pregnancy category: C
Lactation: The drug is known to be excreted in the human breast milk
Pregnancy category:
Patient information leaflet
Generic Name: Lacosamide
Pronounced: (la koe’ sa mide)
Why do we use lacosamide?
Lacosamide is used to treat partial onset seizures and works by decreasing the abnormal electrical activity in the brain.